Gail Petuna Risbridger

List of Publications by Year
in descending order

288 papers	12,130 citations	26630 56 h-index	40979 93 g-index
297 all docs	297 docs citations	297 times ranked	14176 citing authors

#	Article	IF	Citations
1	Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. Genome Biology, 2016, 17, 208.	8.8	912
2	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	21.4	652
3	Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. Journal of Steroid Biochemistry and Molecular Biology, 2004, 92, 221-236.	2.5	266
4	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	21.4	264
5	Breast and prostate cancer: more similar than different. Nature Reviews Cancer, 2010, 10, 205-212.	28.4	212
6	Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Science Translational Medicine, 2019, 11, .	12.4	210
7	Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB Journal, 2008, 22, 1512-1520.	0.5	198
8	Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nature Communications, 2017, 8, 13671.	12.8	182
9	Estrogen receptorâ€“Î² activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFÎ± mediated. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3123-3128.	7.1	178
10	Activins and Inhibins in Endocrine and Other Tumors. Endocrine Reviews, 2001, 22, 836-858.	20.1	170
11	The Dual, Opposing Roles of Estrogen in the Prostate. Annals of the New York Academy of Sciences, 2009, 1155, 174-186.	3.8	169
12	Evidence That Epithelial and Mesenchymal Estrogen Receptor-Î± Mediates Effects of Estrogen on Prostatic Epithelium. Developmental Biology, 2001, 229, 432-442.	2.0	155
13	Elevated Androgens and Prolactin in Aromatase-Deficient Mice Cause Enlargement, But Not Malignancy, of the Prostate Gland*. Endocrinology, 2001, 142, 2458-2467.	2.8	154
14	Local Aromatase Expression in Human Prostate Is Altered in Malignancy. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2434-2441.	3.6	153
15	Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2611-2622.	2.5	145
16	Immuno- and bioactive inhibin and inhibin Î±-subunit expression in rat Leydig cell cultures. Molecular and Cellular Endocrinology, 1989, 66, 119-122.	3.2	143
17	Evaluation of Leydig Cell Function and Gonadotropin Binding in Unilateral and Bilateral Cryptorchidism: Evidence for Local Control of Leydig Cell Function by the seminiferous Tubule. Biology of Reproduction, 1981, 24, 534-540.	2.7	140
18	Aromatase and regulating the estrogen:androgen ratio in the prostate gland. Journal of Steroid Biochemistry and Molecular Biology, 2010, 118, 246-251.	2.5	132

#	Article	IF	Citations
19	Inhibin and activin regulate [3H]thymidine uptake by rat thymocytes and 3T3 cells in vitro. Molecular and Cellular Endocrinology, 1989, 61, 133-138.	3.2	126
20	Oestrogens and prostate cancer.. Endocrine-Related Cancer, 2003, 10, 187-191.	3.1	116
21	Morphometric analysis of the components of the neonatal and the adult rat testis interstitium. Journal of Developmental and Physical Disabilities, 1987, 10, 525-534.	3.6	114
22	Patient-derived Xenografts Reveal that Intraductal Carcinoma of the Prostate Is a Prominent Pathology in BRCA2 Mutation Carriers with Prostate Cancer and Correlates with Poor Prognosis. European Urology, 2015, 67, 496-503.	1.9	112
23	Essential Role for Estrogen Receptor Î² in Stromal-Epithelial Regulation of Prostatic Hyperplasia. Endocrinology, 2007, 148, 566-574.	2.8	106
24	Treating prostate cancer: a rationale for targeting local oestrogens. Nature Reviews Cancer, 2007, 7, 621-627.	28.4	102
25	Formation of human prostate tissue from embryonic stem cells. Nature Methods, 2006, 3, 179-181.	19.0	96
26	The cDNA structure and expression analysis of the genes for the cysteine proteinase inhibitor cystatin C and for beta2-microglobulin in rat brain. FEBS Journal, 1989, 186, 35-42.	0.2	92
27	The Metaplastic Effects of Estrogen on Mouse Prostate Epithelium: Proliferation of Cells with Basal Cell Phenotype¹. Endocrinology, 2001, 142, 2443-2450.	2.8	92
28	Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors. Clinical Cancer Research, 2012, 18, 3562-3570.	7.0	92
29	Direct Response of the Murine Prostate Gland and Seminal Vesicles to Estradiol. Endocrinology, 2002, 143, 4922-4933.	2.8	90
30	A preclinical xenograft model of prostate cancer using human tumors. Nature Protocols, 2013, 8, 836-848.	12.0	90
31	Localization of Activin Î²_A-,Î²_B-, andÎ²_C-Subunits in Human Prostate and Evidence for Formation of New Activin Heterodimers ofÎ²_C-Subunit¹. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4851-4858.	3.6	89
32	Activins as Regulators of Branching Morphogenesis. Developmental Biology, 2001, 238, 1-12.	2.0	89
33	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	12.8	88
34	Evidence That Estrogens Directly Alter Androgen-Regulated Prostate Development*. Endocrinology, 2000, 141, 3471-3477.	2.8	81
35	Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. European Urology, 2017, 72, 492-495.	1.9	81
36	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. European Urology, 2018, 74, 562-572.	1.9	80

#	Article	IF	Citations
37	Regulation of Prostate Branching Morphogenesis by Activin A and Follistatin. Developmental Biology, 2001, 237, 145-158.	2.0	77
38	Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patientâ€derived xenograft (PDX) models. Prostate, 2018, 78, 1262-1282.	2.3	76
39	Estrogenic effects on prostatic differentiation and carcinogenesis. Reproduction, Fertility and Development, 2001, 13, 285.	0.4	74
40	Enduring epigenetic landmarks define the cancer microenvironment. Genome Research, 2018, 28, 625-638.	5.5	74
41	Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling. Journal of Molecular Endocrinology, 2007, 39, 183-188.	2.5	73
42	Human Epithelial Basal Cells Are Cells of Origin of Prostate Cancer, Independent of CD133 Status. Stem Cells, 2012, 30, 1087-1096.	3.2	73
43	Current understanding of hypospadias: relevance of animal models. Nature Reviews Urology, 2015, 12, 271-280.	3.8	73
44	Increased Endogenous Estrogen Synthesis Leads to the Sequential Induction of Prostatic Inflammation (Prostatitis) and Prostatic Pre-Malignancy. American Journal of Pathology, 2009, 175, 1187-1199.	3.8	72
45	Localization of Activin ÂA-, ÂB-, and ÂC-Subunits in Human Prostate and Evidence for Formation of New Activin Heterodimers of ÂC-Subunit. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4851-4858.	3.6	70
46	Activins and Inhibins in Endocrine and Other Tumors. , 2001, 22, 836-858.		68
47	Estrogen-regulated development and differentiation of the prostate. Differentiation, 2008, 76, 660-670.	1.9	67
48	Activin C Antagonizes Activin A in Vitro and Overexpression Leads to Pathologies in Vivo. American Journal of Pathology, 2009, 174, 184-195.	3.8	67
49	Prostatic Tumor Stroma: A Key Player in Cancer Progression. Current Cancer Drug Targets, 2008, 8, 490-497.	1.6	66
50	A community-based model of rapid autopsy in end-stage cancer patients. Nature Biotechnology, 2016, 34, 1010-1014.	17.5	66
51	Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome. Oncotarget, 2015, 6, 16135-16150.	1.8	66
52	Preclinical Models of Prostate Cancer: Patient-Derived Xenografts, Organoids, and Other Explant Models. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030536.	6.2	65
53	New Insights on the Morphology of Adult Mouse Penis1. Biology of Reproduction, 2011, 85, 1216-1221.	2.7	64
54	Growth inhibitory response to activin A and B by human prostate tumour cell lines, LNCaP and DU145. Journal of Endocrinology, 1997, 154, 535-545.	2.6	64

#	Article	IF	Citations
55	Activin Î²C-Subunit Heterodimers Provide a New Mechanism of Regulating Activin Levels in the Prostate. Endocrinology, 2003, 144, 4410-4419.	2.8	63
56	Stem cells in prostate cancer: treating the root of the problem. Endocrine-Related Cancer, 2010, 17, R273-R285.	3.1	60
57	Proteomic Profiling of Human Prostate Cancer-associated Fibroblasts (CAF) Reveals LOXL2-dependent Regulation of the Tumor Microenvironment. Molecular and Cellular Proteomics, 2019, 18, 1410-1427.	3.8	60
58	Effects of Experimental Cryptorchidism on Testicular Function in Adult Rats. Journal of Andrology, 1983, 4, 88-94.	2.0	59
59	The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer. Clinical Cancer Research, 2016, 22, 5539-5552.	7.0	59
60	Fibroblast growth factor receptors and their ligands in the adult rat kidney. Kidney International, 2001, 60, 147-155.	5.2	56
61	A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. Cancer Discovery, 2015, 5, 368-379.	9.4	56
62	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1121-1129.	2.5	56
63	In vitro synthesis and release of inhibin in response to FSH stimulation by isolated segments of seminiferous tubules from normal adult male rats. Molecular and Cellular Endocrinology, 1988, 59, 179-185.	3.2	55
64	Discrete cell- and stage-specific localisation of fibroblast growth factors and receptor expression during testis development. Journal of Endocrinology, 2000, 164, 149-159.	2.6	54
65	A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer. Biomaterials, 2013, 34, 4777-4785.	11.4	53
66	Regulation of the Transcriptional Coactivator FHL2 Licenses Activation of the Androgen Receptor in Castrate-Resistant Prostate Cancer. Cancer Research, 2013, 73, 5066-5079.	0.9	53
67	The influence of BRCA2 mutation on localized prostate cancer. Nature Reviews Urology, 2019, 16, 281-290.	3.8	53
68	Expression of Activin A and Follistatin Core Proteins by Human Prostate Tumor Cell Lines. Endocrinology, 1999, 140, 5303-5309.	2.8	52
69	Î²A- and Î²C-activin, follistatin, activin receptor mRNA and Î²C-activin peptide expression during rat liver regeneration. Journal of Molecular Endocrinology, 2005, 34, 505-515.	2.5	51
70	Specific morphogenetic events in mouse external genitalia sex differentiation are responsive/dependent upon androgens and/or estrogens. Differentiation, 2012, 84, 269-279.	1.9	51
71	Differential Localization of Fibroblast Growth Factor Receptor-i, -2, -3, and -4 in Fetal, Immature, and Adult Rat Testes1. Biology of Reproduction, 1998, 58, 1138-1145.	2.7	50
72	An in vivo model of prostate carcinoma growth and invasion in bone. Cell and Tissue Research, 2002, 307, 337-345.	2.9	50

#	Article	IF	Citations
73	A Preclinical Xenograft Model Identifies Castration-Tolerant Cancer-Repopulating Cells in Localized Prostate Tumors. Science Translational Medicine, 2013, 5, 187ra71.	12.4	50
74	Platelet-derived growth factor ligand and receptor subunit mRNA in the Sertoli and Leydig cells of the rat testis. Molecular and Cellular Endocrinology, 1995, 108, 155-159.	3.2	49
75	Elevated Androgens and Prolactin in Aromatase-Deficient Mice Cause Enlargement, But Not Malignancy, of the Prostate Gland. Endocrinology, 2001, 142, 2458-2467.	2.8	49
76	Inhibins, activins, and follistatins: Expression of mRNAs and cellular localization in tissues from men with benign prostatic hyperplasia. , 1998, 34, 34-43.		47
77	Prostate phenotypes in estrogen-modulated transgenic mice. Trends in Endocrinology and Metabolism, 2002, 13, 163-168.	7.1	47
78	A proâ€tumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, <scp>CXCL12</scp> and mast cell recruitment. Journal of Pathology, 2014, 234, 86-98.	4.5	47
79	Vinclozolin Exposure in Utero Induces Postpubertal Prostatitis and Reduces Sperm Production via a Reversible Hormone-Regulated Mechanism. Endocrinology, 2010, 151, 783-792.	2.8	46
80	In vitro modeling of the prostate cancer microenvironment. Advanced Drug Delivery Reviews, 2014, 79-80, 214-221.	13.7	46
81	Recent progress in our understanding of inhibin in the prostate gland. Journal of Endocrinology, 1998, 157, 1-4.	2.6	44
82	Tissue engineered human prostate microtissues reveal key role of mast cell-derived tryptase in potentiating cancer-associated fibroblast (CAF)-induced morphometric transition in vitro. Biomaterials, 2019, 197, 72-85.	11.4	44
83	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nature Communications, 2018, 9, 4616.	12.8	43
84	Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity. Oncotarget, 2015, 6, 604-616.	1.8	43
85	Morphology of the external genitalia of the adult male and female mice as an endpoint of sex differentiation. Molecular and Cellular Endocrinology, 2012, 354, 94-102.	3.2	42
86	Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. BMC Medicine, 2016, 14, 66.	5.5	42
87	Brief Report: A Bioassay to Identify Primary Human Prostate Cancer Repopulating Cells. Stem Cells, 2011, 29, 1310-1314.	3.2	40
88	Hedgehog signaling is active in human prostate cancer stroma and regulates proliferation and differentiation of adjacent epithelium. Prostate, 2013, 73, 1810-1823.	2.3	40
89	Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrateâ€tolerant cells. BJU International, 2018, 121, 971-978.	2.5	39
90	The contribution of inhibins and activins to malignant prostate disease. Molecular and Cellular Endocrinology, 2001, 180, 149-153.	3.2	38

#	Article	IF	Citations
91	Analysis of the effect of estrogen/androgen perturbation on penile development in transgenic and diethylstilbestrolâ€treated mice. Anatomical Record, 2013, 296, 1127-1141.	1.4	38
92	Expression of fibroblast growth factor-8 in adult rat tissues and human prostate carcinoma cells. Journal of Steroid Biochemistry and Molecular Biology, 1996, 57, 173-178.	2.5	37
93	Transient Neonatal Estrogen Exposure to Estrogen-Deficient Mice (Aromatase Knockout) Reduces Prostate Weight and Induces Inflammation in Late Life. American Journal of Pathology, 2006, 168, 1869-1878.	3.8	37
94	Informing Men about Prostate Cancer Screening: A Randomized Controlled Trial of Patient Education Materials. Journal of General Internal Medicine, 2008, 23, 466-471.	2.6	37
95	Breaking through a roadblock in prostate cancer research: An update on human model systems. Journal of Steroid Biochemistry and Molecular Biology, 2012, 131, 122-131.	2.5	37
96	Early prostate development and its association with late-life prostate disease. Cell and Tissue Research, 2005, 322, 173-181.	2.9	35
97	Estrogen Receptor Î² Activation Impairs Prostatic Regeneration by Inducing Apoptosis in Murine and Human Stem/Progenitor Enriched Cell Populations. PLoS ONE, 2012, 7, e40732.	2.5	35
98	Activins and activin antagonists in the prostate and prostate cancer. Molecular and Cellular Endocrinology, 2012, 359, 107-112.	3.2	35
99	Convergence of regenerative medicine and synthetic biology to develop standardized and validated models of human diseases with clinical relevance. Current Opinion in Biotechnology, 2015, 35, 127-132.	6.6	35
100	The Quantification of Steroidogenesis- Stimulating Activity in Testicular Interstitial Fluid by anin VitroBioassay Employing Adult Rat Leydig Cells*. Endocrinology, 1990, 127, 1967-1977.	2.8	34
101	Hypermethylation of the Inhibin Î±-Subunit Gene in Prostate Carcinoma. Molecular Endocrinology, 2002, 16, 213-220.	3.7	34
102	Gestational changes in prostaglandin production by ovine fetal trophoblast cells. Placenta, 1985, 6, 117-125.	1.5	33
103	Follitropin (FSH) stimulation of inhibin biological and immunological activities by seminiferous tubules and Sertoli cell cultures from immature rats. Molecular and Cellular Endocrinology, 1989, 67, 1-9.	3.2	33
104	Molecular profiling of bladder cancer: Involvement of the TGF-Î² pathway in bladder cancer progression. Cancer Letters, 2008, 265, 27-38.	7.2	33
105	Early-Onset Endocrine Disruptorâ€"Induced Prostatitis in the Rat. Environmental Health Perspectives, 2008, 116, 923-929.	6.0	33
106	Development of the external genitalia: Perspectives from the spotted hyena (Crocuta crocuta). Differentiation, 2014, 87, 4-22.	1.9	33
107	Estrogen receptor subtypes dictate the proliferative nature of the mammary gland. Journal of Endocrinology, 2018, 237, 323-336.	2.6	33
108	Translational offsetting as a mode of estrogen receptor Î±â€dependent regulation of geneÂexpression. EMBO Journal, 2019, 38, e101323.	7.8	33

#	Article	IF	Citations
109	Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer. Cell Reports, 2021, 34, 108585.	6.4	33
110	The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nature Communications, 2021, 12, 5049.	12.8	33
111	Cell-specific expression of Î²C-activin in the rat reproductive tract, adrenal and liver. Molecular and Cellular Endocrinology, 2004, 222, 61-69.	3.2	32
112	Localization of Immunoreactive Î²-Endorphin and Adrenocorticotropic Hormone and Pro-Opiomelanocortin mRNA to Rat Testicular Interstitial Tissue Macrophages. Biology of Reproduction, 1991, 45, 282-289.	2.7	31
113	Developmental response by Leydig cells to acidic and basic fibroblast growth factor. Journal of Steroid Biochemistry and Molecular Biology, 1997, 60, 171-179.	2.5	31
114	Establishment of primary patient-derived xenografts of palliative TURP specimens to study castrate-resistant prostate cancer. Prostate, 2015, 75, 1475-1483.	2.3	31
115	Stimulation of interstitial cell growth after selective destruction of foetal Leydig cells in the testis of postnatal rats. Cell and Tissue Research, 1988, 252, 89-98.	2.9	30
116	Identification of receptor tyrosine kinases in the rat testis. Molecular Reproduction and Development, 1993, 36, 440-447.	2.0	30
117	Inhibin-related proteins in rat prostate. Journal of Endocrinology, 1996, 149, 93-99.	2.6	30
118	Re-evaluation of inhibin Î± subunit as a tumour suppressor in prostate cancer. Molecular and Cellular Endocrinology, 2004, 225, 73-76.	3.2	30
119	High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids. SLAS Discovery, 2021, 26, 1107-1124.	2.7	30
120	Stage-specific inhibin secretion by rat seminiferous tubules. Reproduction, Fertility and Development, 1989, 1, 275.	0.4	29
121	Changes in activin and activin receptor subunit expression in rat liver during the development of CCl4-induced cirrhosis. Molecular and Cellular Endocrinology, 2003, 201, 143-153.	3.2	29
122	Epigenetic regulation of inhibin alpha-subunit gene in prostate cancer cell lines. Journal of Molecular Endocrinology, 2004, 32, 55-67.	2.5	29
123	Activinâ€Î²_c reduces reproductive tumour progression and abolishes cancerâ€associated cachexia in inhibinâ€deficient mice. Journal of Pathology, 2013, 229, 599-607.	4.5	29
124	Evidence That Estrogens Directly Alter Androgen-Regulated Prostate Development. Endocrinology, 2000, 141, 3471-3477.	2.8	29
125	The role of inhibins and activins in prostate cancer pathogenesis.. Endocrine-Related Cancer, 2000, 7, 243-256.	3.1	28
126	Should activin Î²C be more than a fading snapshot in the activin/TGFÎ² family album?. Cytokine and Growth Factor Reviews, 2005, 16, 377-385.	7.2	28

#	Article	IF	Citations
127	Lineage Enforcement by Inductive Mesenchyme on Adult Epithelial Stem Cells across Developmental Germ Layers. Stem Cells, 2009, 27, 3032-3042.	3.2	28
128	Enhancing active surveillance of prostate cancer: the potential of exercise medicine. Nature Reviews Urology, 2016, 13, 258-265.	3.8	28
129	DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation. Cell Death and Differentiation, 2014, 21, 761-773.	11.2	27
130	Activin-Î²_Cmodulates cachexia by repressing the ubiquitin-proteasome and autophagic degradation pathways. Journal of Cachexia, Sarcopenia and Muscle, 2015, 6, 365-380.	7.3	27
131	A rare castrationâ€resistant progenitor cell population is highly enriched in Ptenâ€null prostate tumours. Journal of Pathology, 2017, 243, 51-64.	4.5	27
132	A critical role for estrogen signaling in penis development. FASEB Journal, 2019, 33, 10383-10392.	0.5	27
133	Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2020, 10, 581515.	2.8	27
134	Knowing whatâ€™s growing: Why ductal and intraductal prostate cancer matter. Science Translational Medicine, 2020, 12, .	12.4	27
135	The Metaplastic Effects of Estrogen on Mouse Prostate Epithelium: Proliferation of Cells with Basal Cell Phenotype. Endocrinology, 2001, 142, 2443-2450.	2.8	27
136	Differential Effects of the Destruction of Leydig Cells by Administration of Ethane Dimethane Suiphonate to Postnatal Rats1. Biology of Reproduction, 1989, 40, 801-809.	2.7	26
137	Adult rat Leydig cell cultures: Minimum requirements for maintenance of luteinizing hormone responsiveness and testosterone production. Molecular and Cellular Endocrinology, 1992, 83, 125-132.	3.2	26
138	Searching the internet for information on prostate cancer screening: an assessment of quality. Urology, 2004, 64, 112-116.	1.0	26
139	Regulation of Prostatic Stem Cells by Stromal Niche in Health and Disease. Endocrinology, 2008, 149, 4303-4306.	2.8	26
140	Elevated level of inhibin-Î± subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer. British Journal of Cancer, 2009, 100, 1784-1793.	6.4	26
141	17Î²-Estradiol Induces Apoptosis in the Developing Rodent Prostate Independently of ERÎ± or ERÎ². Endocrinology, 2006, 147, 191-200.	2.8	25
142	The effect of testicular macrophages and interleukin-1 on testosterone production by purified adult rat Leydig cells cultured under in vitro maintenance conditions. Endocrinology, 1993, 132, 186-192.	2.8	25
143	Hypermethylation of the Inhibin Â-Subunit Gene in Prostate Carcinoma. Molecular Endocrinology, 2002, 16, 213-220.	3.7	25
144	Elevated Expression of Inhibin Î± in Prostate Cancer. Journal of Urology, 2004, 171, 192-196.	0.4	24

#	Article	IF	Citations
145	A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts. Oncotarget, 2016, 7, 60475-60490.	1.8	24
146	Loss of the Expression and Localization of InhibinÎ± -Subunit in High Grade Prostate Cancer1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 969-975.	3.6	23
147	Anti-androgenic action by red clover-derived dietary isoflavones reduces non-malignant prostate enlargement in aromatase knockout (arko) mice. Prostate, 2003, 56, 54-64.	2.3	23
148	Expression of Estrogen Receptor Alpha and Beta is Decreased in Hypospadias. Journal of Urology, 2012, 187, 1427-1433.	0.4	23
149	Mammary stem cells and parity-induced breast cancer protection- new insights. Journal of Steroid Biochemistry and Molecular Biology, 2017, 170, 54-60.	2.5	22
150	SCA-1 Labels a Subset of Estrogen-Responsive Bipotential Repopulating Cells within the CD24 + CD49f hi Mammary Stem Cell-Enriched Compartment. Stem Cell Reports, 2017, 8, 417-431.	4.8	22
151	Loss of the Expression and Localization of Inhibin Â-Subunit in High Grade Prostate Cancer. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 969-975.	3.6	22
152	The therapeutic potential of blocking the activin signalling pathway. Cytokine and Growth Factor Reviews, 2013, 24, 477-484.	7.2	21
153	Aromatase transgenic upregulation modulates basal cardiac performance and the response to ischemic stress in male mice. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 306, H1265-H1274.	3.2	21
154	Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer. Cancers, 2022, 14, 503.	3.7	21
155	Influence of the cryptorchid testis on the regeneration of rat Leydig cells after administration of ethane dimethane sulphonate. Journal of Endocrinology, 1987, 112, 197-NP.	2.6	20
156	The inhibin/activin signalling pathway in human gonadal and adrenal cancers. Molecular Human Reproduction, 2014, 20, 1223-1237.	2.8	20
157	Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target. Neoplasia, 2019, 21, 389-400.	5.3	20
158	Expression of Activin A and Follistatin Core Proteins by Human Prostate Tumor Cell Lines. Endocrinology, 1999, 140, 5303-5309.	2.8	20
159	Physiology of the Male Accessory Sex StructuresThe Prostate Gland, Seminal Vesicles, and Bulbourethral Glands. , 2006, , 1149-1172.		19
160	Mouse hypospadias: A critical examination and definition. Differentiation, 2016, 92, 306-317.	1.9	19
161	A loss of estrogen signaling in the aromatase deficient mouse penis results in mild hypospadias. Differentiation, 2019, 109, 42-52.	1.9	19
162	PDX: Moving Beyond Drug Screening to Versatile Models for Research Discovery. Journal of the Endocrine Society, 2020, 4, bvaa132.	0.2	19

#	Article	IF	Citations
163	Effect of serum and serum lipoproteins on testosterone production by adult rat leydig cells in vitro. Journal of Steroid Biochemistry and Molecular Biology, 1992, 43, 581-589.	2.5	18
164	Obesity does not promote tumorigenesis of localized patient-derived prostate cancer xenografts. Oncotarget, 2016, 7, 47650-47662.	1.8	18
165	Discrete stimulatory effects of platelet-derived growth factor (PDGF-BB) on Leydig cell steroidogenesis. Molecular and Cellular Endocrinology, 1993, 97, 125-128.	3.2	17
166	Primary Culture and Propagation of Human Prostate Epithelial Cells. Methods in Molecular Biology, 2012, 945, 365-382.	0.9	17
167	A comparative assessment of Î±-lipoic acid N-phenylamides as non-steroidal androgen receptor antagonists both on and off gold nanoparticles. Bioorganic Chemistry, 2012, 40, 1-5.	4.1	17
168	Sex specific retinoic acid signaling is required for the initiation of urogenital sinus bud development. Developmental Biology, 2014, 395, 209-217.	2.0	17
169	Kallikreinâ€related peptidase 4 induces cancerâ€associated fibroblast features in prostateâ€derived stromal cells. Molecular Oncology, 2017, 11, 1307-1329.	4.6	17
170	Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer. Clinical Epigenetics, 2020, 12, 48.	4.1	17
171	Differential Localization of Inhibin Subunit Proteins in the Ovine Testis during Fetal Gonadal Development. Endocrinology, 1999, 140, 979-986.	2.8	17
172	Requirement for heparan sulphate proteoglycans to mediate basic fibroblast growth factor (FGF-2)-induced stimulation of Leydig cell steroidogenesis. Journal of Steroid Biochemistry and Molecular Biology, 1995, 54, 245-250.	2.5	16
173	The path toward identifying prostatic stem cells. Differentiation, 2008, 76, 671-681.	1.9	16
174	The power and perils of animal models with urogenital anomalies: Handle with care. Journal of Pediatric Urology, 2014, 10, 699-705.	1.1	16
175	Comprehensive evaluation of targeted multiplex bisulphite PCR sequencing for validation of DNA methylation biomarker panels. Clinical Epigenetics, 2020, 12, 90.	4.1	16
176	Inhibin secretion is influenced by Ley dig cells: evidence from studies using the cytotoxin ethane dimethane sulphonate (EDS). Journal of Developmental and Physical Disabilities, 1989, 12, 273-280.	3.6	15
177	Site of Macrophage Inhibition of Luteinizing Hormone-Stimulated Testosterone Production by Purified Leydig Cells1. Biology of Reproduction, 1994, 50, 363-367.	2.7	15
178	The informed man: Attitudes and information needs on prostate cancer screening. The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender, 2005, 2, 414-420.	0.2	15
179	Peripubertal aromatase inhibition in male rats has adverse long-term effects on bone strength and growth and induces prostatic hyperplasia. Journal of Endocrinology, 2010, 207, 27-34.	2.6	15
180	Preliminary investigations into triazole derived androgen receptor antagonists. Bioorganic and Medicinal Chemistry, 2014, 22, 2692-2706.	3.0	15

#	Article	IF	Citations
181	Humanization of the Prostate Microenvironment Reduces Homing of PC3 Prostate Cancer Cells to Human Tissue-Engineered Bone. Cancers, 2018, 10, 438.	3.7	15
182	Current perspectives of inhibin biology. European Journal of Endocrinology, 1990, 122, 673-682.	3.7	14
183	Cancer progression: is inhibin Î± from Venus or Mars?. Cytokine and Growth Factor Reviews, 2004, 15, 291-296.	7.2	14
184	High-Aspect-Ratio SU-8-Based Optofluidic Device for Ammonia Detection in Cell Culture Media. ACS Sensors, 2020, 5, 2523-2529.	7.8	14
185	CRISP3 expression drives prostate cancer invasion and progression. Endocrine-Related Cancer, 2020, 27, 415-430.	3.1	14
186	CORRELATIONS BETWEEN FIBROBLAST ANDROGEN RECEPTOR LEVELS and CLINICAL FEATURES IN ABNORMAL MALE SEXUAL DIFFERENTIATION and INFERTILITY. Australian and New Zealand Journal of Medicine, 1983, 13, 335-341.	0.5	13
187	11 Intragonadal control mechanisms. Bailliere's Clinical Endocrinology and Metabolism, 1987, 1, 223-243.	1.0	13
188	The effect of insulin on inhibin production in isolated seminiferous tubule segments from adult rats cultured in vitro. Molecular and Cellular Endocrinology, 1989, 61, 209-216.	3.2	13
189	The role of calcium in luteinizing hormone/human chorionic gonadotrophin stimulation of Leydig cell immunoactive inhibin secretion in vitro. Molecular and Cellular Endocrinology, 1991, 75, 49-56.	3.2	13
190	Evidence that heparin binding autocrine factors modulate testosterone production by the adult rat Leydig cell. Molecular and Cellular Endocrinology, 1996, 118, 57-63.	3.2	13
191	Comparative Biomarker Expression and RNA Integrity in Biospecimens Derived from Radical Retropubic and Robot-Assisted Laparoscopic Prostatectomies. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1755-1765.	2.5	13
192	Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An Assessment of Existing and Newly Developed Algorithms. Medical Decision Making, 2018, 38, 954-967.	2.4	13
193	Effect of unilateral cryptorchidism on the intertubular tissue of the adult rat testis: evidence for intracellular changes within the Leydig cells. Journal of Developmental and Physical Disabilities, 1988, 11, 209-223.	3.6	12
194	Effect of ethane dimethane sulphonate on proopiomelanocortin (POMC) mRNA and POMC-derived peptides in the rat testis. Molecular and Cellular Endocrinology, 1989, 65, 203-207.	3.2	12
195	Evaluation of the effect of peritubular cell secretions and the testicular paracrine factor P-Mod-S on Leydig cell steroidogenesis and immunoactive inhibin production. Journal of Developmental and Physical Disabilities, 1992, 15, 73-83.	3.6	12
196	The in vivo effect of red clover diet on ventral prostate growth in adult male mice. Reproduction, Fertility and Development, 2001, 13, 325.	0.4	12
197	Establishing a cryopreservation protocol for patientâ€derived xenografts of prostate cancer. Prostate, 2019, 79, 1326-1337.	2.3	12
198	Androgen receptor enhancer amplification in matched patientâ€derived xenografts of primary and castrateâ€resistant prostate cancer. Journal of Pathology, 2021, 254, 121-134.	4.5	12

#	Article	IF	Citations
199	Differences in proteins synthesized by fibroblasts from normal individuals and patients with complete testicular feminization.. Journal of Clinical Investigation, 1982, 69, 99-103.	8.2	12
200	Epidermal growth factor increases inhibin synthesis by isolated segments of rat seminiferous tubules. Journal of Endocrinology, 1989, 123, 213-219.	2.6	11
201	Acute effects of ethane dimethane sulfonate (EDS) on the structure of the cauda epididymidis in the rat: selective destruction of clear cells in the proximal cauda region. Reproduction, Fertility and Development, 1993, 5, 295.	0.4	11
202	New perspectives on growth factor-sex steroid interaction in the prostate. Cytokine and Growth Factor Reviews, 2003, 14, 5-16.	7.2	10
203	Computer-based detection of neonatal changes to branching morphogenesis reveals different mechanisms of and predicts prostate enlargement in mice haplo-insufficient for bone morphogenetic protein 4. Journal of Pathology, 2005, 206, 52-61.	4.5	10
204	Mast Cell-Derived SAMD14 Is a Novel Regulator of the Human Prostate Tumor Microenvironment. Cancers, 2021, 13, 1237.	3.7	10
205	Growth Factors in the Control of Testicular Function. , 1993, , 411-438.		10
206	Elevated seminal plasma estradiol and epigenetic inactivation of ESR1 and ESR2 is associated with CP/CPPS. Oncotarget, 2018, 9, 19623-19639.	1.8	10
207	The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer. European Urology, 2017, 71, 748-749.	1.9	9
208	CX-5461 Sensitizes DNA Damage Repairâ€“proficient Castrate-resistant Prostate Cancer to PARP Inhibition. Molecular Cancer Therapeutics, 2021, 20, 2140-2150.	4.1	9
209	Variation in the Effect of a Nongonadotropic Leydig Cell Stimulating Factor in Testicular Interstitial Fluid After Exposure of the Testis to a Single Episode of Heat Treatment. Journal of Andrology, 1987, 8, 247-252.	2.0	8
210	Multiple factors with steroidogenesis-regulating activity in testicular interbular fluid from normal and experimentally cryptorchid adult rats. Steroids, 1994, 59, 676-685.	1.8	8
211	Synthesis and preliminary investigations into novel 1,2,3-triazole-derived androgen receptor antagonists inspired by bicalutamide. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4948-4953.	2.2	8
212	Activin-Î²C modulates gonadal, but not adrenal tumorigenesis in the inhibin deficient mice. Molecular and Cellular Endocrinology, 2015, 409, 41-50.	3.2	8
213	Patient-Derived Prostate Cancer: from Basic Science to the Clinic. Hormones and Cancer, 2016, 7, 236-240.	4.9	8
214	Towards Best Practice in Establishing Patient-Derived Xenografts. Molecular and Translational Medicine, 2017, , 11-28.	0.4	8
215	Recent advances in the human physiology of inhibin secretion. Journal of Endocrinological Investigation, 1990, 13, 611-624.	3.3	7
216	6 The physiology of testicular inhibin and related proteins. Bailliere's Clinical Endocrinology and Metabolism, 1992, 6, 355-372.	1.0	7

#	Article	IF	Citations
217	Pro-opiomelanocortin (POMC) gene expression, as identified by in situ hybridization, in purified populations of interstitial macrophages and Leydig cells of the adult rat testis. Reproduction, Fertility and Development, 1993, 5, 545.	0.4	7
218	Inhibition of compensatory renal growth by the N-terminus of a sheep-derived peptide. Regulatory Peptides, 2009, 152, 48-53.	1.9	7
219	Prostate-Regenerating Capacity of Cultured Human Adult Prostate Epithelial Cells. Cells Tissues Organs, 2010, 191, 203-212.	2.3	7
220	Human Cell Lines as Tools of Our Trade: â€œLaying It on the (Cell) Lineâ€• Molecular Endocrinology, 2015, 29, 1-2.	3.7	7
221	The prognostic value of stromal FK506â€binding protein 1 and androgen receptor in prostate cancer outcome. Prostate, 2017, 77, 185-195.	2.3	7
222	Age Related Differences in Responsiveness to Sildenafil and Tamsulosin are due to Myogenic Smooth Muscle Tone in the Human Prostate. Scientific Reports, 2017, 7, 10150.	3.3	7
223	Cancer-associated fibroblasts of the prostate promote a compliant and more invasive phenotype in benign prostate epithelial cells. Materials Today Bio, 2020, 8, 100073.	5.5	7
224	Mysterious inhibitory cell regulator investigated and found likely to be secretogranin II related. PeerJ, 2017, 5, e3833.	2.0	7
225	Effects of steroids on fibroblasts: Identification of glucocorticoid-regulated proteins by two-dimensional gel electrophoresis. Molecular and Cellular Endocrinology, 1983, 30, 303-312.	3.2	6
226	Steroidogenesis-Stimulating Activity in the Gonads: Comparison of Rat Testicular Fluid with Bovine and Human Ovarian Follicular Fluids1. Biology of Reproduction, 1991, 44, 937-944.	2.7	6
227	Novel imaging of the prostate reveals spontaneous gland contraction and excretory duct quiescence together with different drug effects. FASEB Journal, 2018, 32, 1130-1138.	0.5	6
228	OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer. Scientific Reports, 2022, 12, 6094.	3.3	6
229	Fibroblast studies on clinical androgen insensitivity. The Journal of Steroid Biochemistry, 1983, 19, 583-586.	1.1	5
230	Role of activin C in normal ovaries and granulosa cell tumours of mice and humans. Reproduction, Fertility and Development, 2018, 30, 958.	0.4	5
231	Oxytocin receptor antagonists as a novel pharmacological agent for reducing smooth muscle tone in the human prostate. Scientific Reports, 2021, 11, 6352.	3.3	5
232	A humanized orthotopic tumor microenvironment alters the bone metastatic tropism of prostate cancer cells. Communications Biology, 2021, 4, 1014.	4.4	5
233	Proâ€tumorigenic role of ERÎ± in prostate cancer cells. Aging, 2015, 7, 356-357.	3.1	5
234	Neuroendocrine cells in prostate cancer correlate with poor outcomes: A systematic review and metaâ€analysis.. BJU International, 2021, , .	2.5	5

#	Article	IF	Citations
235	Gonadotrophin and Steroid Binding to Adrenal Cortex Tissue of Female Brushtail Possum, Trichosurus vulpecula. Australian Journal of Zoology, 1985, 33, 831.	1.0	4
236	Local regulation of leydig cell function by inhibitors of steroidogenic activity. Cell Biology International Reports, 1992, 16, 399-406.	0.6	4
237	Stimulatory and inhibitory factors of Leydig cell steroidogenesis are secreted simultaneously by the rat seminiferous tubules and do not affect Leydig cell inhibin production in vitro. Reproduction, Fertility and Development, 1994, 6, 693.	0.4	4
238	The complexities of identifying a cell of origin for human prostate cancer. Asian Journal of Andrology, 2011, 13, 118-119.	1.6	4
239	Searching for candidate genes in familial BRCAX mutation carriers with prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 120.e9-120.e16.	1.6	4
240	Parity reduces mammary repopulating activity but does not affect mammary stem cells defined as CD24â€‰+â€‰CD29/CD49fhi in mice. Breast Cancer Research and Treatment, 2020, 183, 565-575.	2.5	4
241	Reproduction, development, and the early origins of adult disease. Cell and Tissue Research, 2005, 322, 3-3.	2.9	3
242	A Versatile Monoclonal Antibody Specific to Human SERPINB5. Hybridoma, 2012, 31, 333-339.	0.4	3
243	Cross-species stromal signaling programs human embryonic stem cell differentiation. Differentiation, 2014, 87, 76-82.	1.9	3
244	Re-evaluating the role of activin-Î²C in cancer biology. Cytokine and Growth Factor Reviews, 2015, 26, 463-470.	7.2	3
245	Novel xenografts in miceâ€”a new wave of preclinical models. Nature Reviews Urology, 2015, 12, 540-541.	3.8	3
246	Interactions between the seminiferous tubules and Leydig cells of the testis. Reproduction, Fertility and Development, 1990, 2, 219.	0.4	3
247	Association of "DNA damage signature" with poor outcome in early prostate cancer.. Journal of Clinical Oncology, 2015, 33, 13-13.	1.6	3
248	Hidden clues in prostate cancer â€“ Lessons learned from clinical and pre-clinical approaches on diagnosis and risk stratification. Cancer Letters, 2022, 524, 182-192.	7.2	3
249	Regulation of Leydig cell function by inhibins and activins. Animal Reproduction Science, 1996, 42, 343-349.	1.5	2
250	To target or not to target the enemy within localized prostate cancer. Cell Cycle, 2013, 12, 3349-3350.	2.6	2
251	Over-Expression of Activin-Î²C Is Associated with Murine and Human Prostate Disease.. Hormones and Cancer, 2017, 8, 100-107.	4.9	2
252	Regional localization of activin-Î² A , activin-Î² C , follistatin, proliferation, and apoptosis in adult and developing mouse prostate ducts. Gene Expression Patterns, 2017, 23-24, 70-79.	0.8	2

#	Article	IF	Citations
253	5.17 Three-Dimensional Bioengineered Cancer Models. , 2017, , 303-328.		2
254	Endocrine Disruption in the Male. , 2007, , 33-62.		2
255	Endocrinology of the Prostate. , 2010, , 2592-2609.		2
256	Castrate-tolerant cells: what are the implications for the treatment of localized prostate cancer?. Asian Journal of Andrology, 2013, 15, 3.	1.6	2
257	Editorial: The Future of Our Basic Science and Scientists. Molecular Endocrinology, 2015, 29, 1673-1674.	3.7	1
258	Patient-Derived Xenograft Models of Prostate Tumors. , 2017, , 217-228.		1
259	Activins and Inhibins in Cancer Progression. , 2008, , 411-423.		1
260	Association of androgen receptor (AR) copy number gain with ARV7 expression and response to chemotherapy.. Journal of Clinical Oncology, 2018, 36, 180-180.	1.6	1
261	2. Advancing the utility of models of organ development. Reproduction, Fertility and Development, 2003, 15, 2.	0.4	1
262	Contemporary approaches to prostate cancer research. Expert Review of Endocrinology and Metabolism, 2011, 6, 299-300.	2.4	0
263	1608 SPONTANEOUS CONTRACTIONS IN THE TRANSITION ZONE OF PROSTATES FROM MEN WITH BENIGN PROSTATIC HYPERPLASIA OR ENLARGEMENT ARE NOT BLOCKED BY TAMSULOSIN. Journal of Urology, 2013, 189, .	0.4	0
264	Are we disrupted?. Endocrine-Related Cancer, 2014, 21, E1-E2.	3.1	0
265	MP31-07 ESTROGEN RECEPTOR Î± REGULATES PROLIFERATION IN PTEN NULL PROSTATE CANCER. Journal of Urology, 2014, 191, .	0.4	0
266	771: Targeting MYC-driven growth and proliferation in prostate cancer. European Journal of Cancer, 2014, 50, S185.	2.8	0
267	MP61-04 GENOMIC PROFILING OF KCONFAB MEN WITH A BRCA MUTATION STATUS AND PROSTATE CANCER. Journal of Urology, 2015, 193, .	0.4	0
268	MP31-09 THE EFFECTS OF CURRENTLY USED ANTI-HYPERTENSIVES ON THE CONTRACTILITY OF THE HUMAN PROSTATE GLAND. Journal of Urology, 2015, 193, .	0.4	0
269	MP44-12 ESTROGEN DIRECTLY MODULATES SPONTANEOUS CONTRACTILITY WITHIN THE HUMAN PROSTATE. Journal of Urology, 2016, 195, .	0.4	0
270	MP44-15 SPONTANEOUS MYOGENIC CONTRACTILITY IN THE HUMAN PROSTATE GLAND: IMPLICATIONS FOR THE TREATMENT OF LUTS ASSOCIATED WITH BPH.. Journal of Urology, 2016, 195, .	0.4	0

#	Article	IF	Citations
271	Endocrinology of Benign Prostatic Hyperplasia and Prostate Cancer. , 2016, , 2467-2484.e5.		0
272	Foreword to 'Estrogens and Male Health'. Reproduction, Fertility and Development, 2001, 13, I.	0.4	0
273	57. Temporo-spatial alterations in prostate branching morphogenesis in estrogen-deficient aromatase knockout (ArKO) mice. Reproduction, Fertility and Development, 2003, 15, 57.	0.4	0
274	Tumour Stroma Control of Human Prostate Cancer Stem Cells. , 2013, , 111-125.		0
275	Adult Prostate Stem Cells. Pancreatic Islet Biology, 2014, , 265-286.	0.3	0
276	Abstract 3575: Integration of estradiol signaling at the translational and transcriptional level in prostate cancer cells.. , 2013, , .		0
277	Abstract B25: DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation. , 2013, , .		0
278	Abstract 2106: Estrogen receptor alpha drives proliferation of prostate cancer through PI3K and MAPK signaling. , 2014, , .		0
279	Abstract 5181: Dual inhibition of RNA Pol I transcription and PIM kinase as a new therapy to treat prostate cancer. , 2016, , .		0
280	Abstract 4809: Combination therapy targeting ribosome biogenesis and mRNA translation provides a novel and potent therapeutic approach to treat MYC-driven malignancy. , 2016, , .		0
281	Abstract B23: Inhibition of ribosomal RNA synthesis as a new therapeutic approach to treat advanced prostate cancer. , 2017, , .		0
282	Mutation of the DNA damage gene signature to predict for better outcome in malignant melanoma.. Journal of Clinical Oncology, 2017, 35, e21036-e21036.	1.6	0
283	Abstract 1997: Charting the DNA methylation landscape of prostate cancer associated fibroblasts. , 2017, , .		0
284	Oxytocin as a pharmacological target for benign prostatic hyperplasia. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-3-32.	0.0	0
285	Abstract 5234: Transcriptome profiling of single prostate cancer cells following androgen deprivation. , 2018, , .		0
286	Abstract B100: High-risk pathologic and genomic features of BRCA2-mutant prostate cancer. , 2018, , .		0
287	Abstract 155: Cysteine-rich secretory protein 3 expression leads to invasive prostate cancer by modulating cell motility. , 2019, , .		0
288	Activins and Leydig Cell Development Differentiation, and Disease. , 2007, , 323-331.		0